Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 111-117

  Grünwald, Viktor ^a   Merseburger, Axel S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Axitinib; Renal cell carcinoma; Tivozanib; Tyrosine kinase inhibitor; VEGF

Indexed keywords

AXITINIB; BEVACIZUMAB; RABEPRAZOLE; SORAFENIB;

ADVANCED CANCER; ALGORITHM; ANOREXIA; APNEA; AREA UNDER THE CURVE; ASTHENIA; CANCER SURVIVAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTESTINE ISCHEMIA; KIDNEY METASTASIS; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PANCREATITIS; PHARMACODYNAMICS; REVIEW; SEIZURE; SIDE EFFECT; STOMATITIS; THROMBOEMBOLISM; TREATMENT INDICATION; WEIGHT REDUCTION;

EID: 84873928134     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S23273     Document Type: Review

References (43)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-3590.
2. Escudier BJ, Pluzanska A, Koralewski P, Ravaud A. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2008;370(9605):2103-2111.
3. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
4. Hudes GR, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
5. Motzer RJ, Escudier BJ, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
6. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10): 1556-1563.
7. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26(22): 3743-3748.
8. Porta C, Procopio G, Cartenì G, et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011;108(8 Pt 2): E250-E257.
9. Di Lorenzo G, Cartenì G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib refractory metastatic renal cell cancer. J Clin Oncol. 2009;27(27):4469-4474.
10. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
11. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170(6 Pt 1):2163-2172.
12. Zhuang Z, Gnarra JR, Dudley CF, Zbar B, Linehan WM, Lubensky IA. Detection of von Hippel Lindau disease gene mutations in paraffnembedded sporadic renal cell carcinoma specimens. Mod Pathol. 1996;9(8):838-842.
13. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995;1(8):822-826.
14. Patard J-J, Pignot G, Escudier B, et al. ICUD-EAU international consultation on kidney cancer 2010: treatment of metastatic disease. Eur Urol. 2011;60(4):684-690.
15. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398-406.
16. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(27):4462-4468.
17. Weikert S, Kempkensteffen C, Busch J, et al. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J Urol. 2011. [Epub ahead of print.]
18. Amato RJ, Jac J, Giessinger S, Saxena S, Willis J P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115(11):2438-2446.
19. Mackenzie MJ, Rini BI, Elson P, et al. Temsirolimus in VEGF refractory metastatic renal cell carcinoma. Ann Oncol. 2011;22(1):145-148.
20. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884-896.
21. Wickman G, Hallin M, Dillon R, et al. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG013736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Cancer Res. 2003;44:A3780.
22. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165(1):35-52.
23. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610-2621.
24. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24): 5474-5483.
25. Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC. Meta-analysis of contribution of genetic polymorphisms in drugmetabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012;68(5):645-655.
26. Tortorici MA, Toh M, Rahavendran S V, et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs. 2011;29(6):1370-1380.
27. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21(21):3955-3964.
28. Flaherty KT, Rosen MA, Heitjan D F, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008;7(4):496-501.
29. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmaco dynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26(28): 4572-4578.
30. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005;23(24):5464-5473.
31. Rini BI, Cohen D P, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763-773.
32. Rini BI, Schiller JH, Fruehauf J P, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841-3849.
33. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: a phase II study. Lancet Oncol. 2007;8(11):975-984.
34. Krajewski KM, Guo M, van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011;59(5):856-862.
35. Motzer RJ, de La Motte Rouge T, Harzstark AL, et al. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. J Clin Oncol. 2011;29(Supp l):Abstr 4547.
36. Escudier B, Loomis AK, Kaprin A, et al. Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS Trial). Eur J Cancer. 2011;47(Suppl 1):Abstr 7103.
37. Motzer RJ, Escudier BJ, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet. 2008;372(9637):449-456.
38. Gr̈nwald V, Soltau J, Ivanyi P, Rentschler J, Reuter CWM, Drevs J. Molecular targeted therapies for solid tumors: management of side effects. Onkologie. 2009;32(3):129-138.
39. Horowitz JR, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxidedependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17(11): 2793-2800.
40. Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010;101(4):963-968.
41. Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol. 2011;60(6):1163-1170.
42. Busch J, Seidel C, Weikert S, et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011;11(1):295.
43. Heng DYC, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011;117(12): 2637-2642.